Iovance Biotherapeutics Inc. (IOVA)
NASDAQ
Closed
Oct 6, 2026
Day's Range
12.9252 wk Range
1.76Overview - IOVA - Iovance Biotherapeutics Inc.
Key Statistics
Valuation
Enterprise Value
4.36B
P/E (Trailing)
‪-10.09‬
P/E (Forward)
‪-37.54‬
PEG Ratio
‪0.15‬
Price / Sales (TTM)
‪14.20‬
Price / Book
‪6.27‬
EV / EBITDA
‪-16.81‬
Profitability
Gross Margin
‪56.10%‬
Profit Margin
‪-89.09%‬
Operating Margin
‪-52.26%‬
Return on Assets
‪-20.30%‬
Return on Equity
‪-40.36%‬
Ownership
Shares Outstanding
452.97M
Float
394.31M
Short % of Shares Outstanding
‪20.80%‬
Held by Insiders
‪0.35%‬
Held by Institutions
‪70.67%‬
Price stats
Beta
‪0.83‬
50-Day Avg
‪7.17‬
200-Day Avg
‪4.36‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
9 analysts
Average price target
‪$ 10.00‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - IOVA - Iovance Biotherapeutics Inc.
Peers - IOVA - Iovance Biotherapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- IOIOVANASDAQIovance Biotherapeutics, Inc.4.98BMarket Cap+80.82%52-week change-10.09P/E (Trailing)‪-89.09%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - IOVA - Iovance Biotherapeutics Inc.
About
Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for cancer. The company specializes in tumor-infiltrating lymphocyte, or TIL, therapies designed to use a patient’s own immune cells to recognize and attack solid tumors. Its product…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
